Clinical Trial

Investigating the Adjunctive Use of Mirabegron in the Early Post-Rezum Procedure Period

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The investigators propose conducting a randomized controlled trial at the Men's Health Clinic to evaluate whether patients who start and continue mirabegron postoperatively after undergoing Rezum therapy experience enhanced patient-reported outcomes, improved quality of life (QoL), and comparable rates of adverse events. There are no predicted adverse events of this study. There are no identified potential harms of this study.
Trial Details
NCT Number NCT07017439
Lead Sponsor University of Manitoba
Conditions Benign Prostate Hypertrophy(BPH)
Enrollment 50 participants
Start Date 2025-08
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-06-12